Table 1.

Treatment exposure

P#	Prior treatment (line)	Time on prior therapy (months)	Line of LEN + EVE treatment	Discontinued LEN + EVE treatment	Reason for discontinuation	Time on therapy (months)	Follow-up (months)
	Prior TKI
1	Sunitinib (1)	0.8	2nd	Yes	PD	15c	17
3	Pazopaniba (1)	1.5			Start new
	Cabozantinibb (2)	0.5	3rd	Yes	anticancer regimen	7d	9
	Prior ICI
4	Ipilimumab + nivolumab (1)	1	2nd	Yes	AE	8	9
5	Ipilimumab + nivolumab (1)	2	2nd	No	NA	6+	11+
7	Ipilimumab + nivolumabb (1)	1	2nd	Yes	AE	7	9+
	Prior TKI and ICI
2	Sunitinib (1)	2
	Nivolumab + lenvatinib (2)	3	3rd	Yes	PD	8	11
6	Cabozantinibb (1)	1.5
	Ipilimumab + nivolumab (2)	1.5	3rd	Yes	PD	3	4

^aPatient had mixed response.

^bDiscontinued because of toxicity rather than disease progression.

^cTreatment was discontinued for 5 days due to toxicity, then resumed due to progression of brain metastasis.

^dTreatment was discontinued for 5 weeks because of the approval of nivolumab plus ipilimumab combination in mRCC but was later resumed due to progression of skin lesions on the ICI combination.

AE, adverse event; EVE, everolimus; ICI, immune checkpoint inhibitor; LEN, lenvatinib; NA, not applicable: P, patient; PD, progressive disease; TKI, tyrosine kinase inhibitor.